American Century Companies Inc. Cuts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

American Century Companies Inc. decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,921,397 shares of the medical equipment provider’s stock after selling 621,555 shares during the quarter. Zimmer Biomet accounts for approximately 0.4% of American Century Companies Inc.’s portfolio, making the stock its 28th largest position. American Century Companies Inc. owned about 2.97% of Zimmer Biomet worth $625,477,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Mizuho Securities USA LLC grew its holdings in shares of Zimmer Biomet by 42.9% during the fourth quarter. Mizuho Securities USA LLC now owns 18,868 shares of the medical equipment provider’s stock worth $1,993,000 after purchasing an additional 5,662 shares in the last quarter. Sciencast Management LP boosted its stake in Zimmer Biomet by 35.5% in the fourth quarter. Sciencast Management LP now owns 9,131 shares of the medical equipment provider’s stock worth $965,000 after buying an additional 2,391 shares in the last quarter. Sector Gamma AS boosted its stake in Zimmer Biomet by 29.9% in the fourth quarter. Sector Gamma AS now owns 137,714 shares of the medical equipment provider’s stock worth $14,547,000 after buying an additional 31,714 shares in the last quarter. Northwest & Ethical Investments L.P. purchased a new stake in Zimmer Biomet in the fourth quarter worth approximately $1,934,000. Finally, iA Global Asset Management Inc. boosted its stake in Zimmer Biomet by 18.2% in the fourth quarter. iA Global Asset Management Inc. now owns 13,026 shares of the medical equipment provider’s stock worth $1,376,000 after buying an additional 2,006 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $110.79 on Friday. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $22.05 billion, a P/E ratio of 24.90, a P/E/G ratio of 1.95 and a beta of 1.04. The business has a fifty day simple moving average of $106.74 and a two-hundred day simple moving average of $106.93. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the company earned $2.20 earnings per share. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Analyst Ratings Changes

Several brokerages have issued reports on ZBH. Stifel Nicolaus upped their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Barclays cut their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Truist Financial reaffirmed a “hold” rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. JMP Securities reissued a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Raymond James dropped their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $124.15.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.